Login to Your Account



Phase III Clinical Trials Update: November 2011


Monday, December 12, 2011

Company (Location)

Product

Description

Indication

Status (Date)#


AUTOIMMUNE

Genzyme Corp. (Cambridge, Mass.)

Lemtrada

Alemtuzumab

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription